title: Pharmacotherapy for end-stage coronary artery disease.
abstract: BACKGROUND
  Coronary artery disease remains the leading cause of mortality in the industrialized world. Despite advances in surgical and catheter-based interventions, a select number of patients remain with no options for invasive therapy. The goal of this review is to discuss the current status of pharmacotherapeutic interventions to treat end-stage coronary artery disease.
  
  
  METHODS
  Literature review on the topic of therapeutic angiogenesis from 1980 to 2009.
  
  
  RESULTS
  Insight into current therapeutic strategies employed to manage end-stage coronary artery disease.
  
  
  CONCLUSIONS
  A promising approach focuses on augmenting the endogenous angiogenic response to chronic myocardial ischemia via the use of growth factors.
authors.affiliation: Beth Israel Deaconess Medical Center, Harvard Medical School, Department of Surgery, LMOB 9B, 110 Francis Street, Boston, MA 02215, USA.
authors.forename: Neel R
authors.initials: NR
authors.lastname: Sodha
authors.forename: Louis M
authors.initials: LM
authors.lastname: Chu
authors.forename: Munir
authors.initials: M
authors.lastname: Boodhwani
authors.forename: Frank W
authors.initials: FW
authors.lastname: Sellke
mesh_terms: D000818:Animals; D001158:Arteries; D003324:Coronary Artery Disease / Q000188:drug therapy / Q000235:genetics / Q000503:physiopathology*; D015316:Genetic Therapy; D006801:Humans; D051379:Mice; D009389:Neovascularization, Pathologic / Q000235:genetics*; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics*
chemical_list: D042461:Vascular Endothelial Growth Factor A